Hepatitis C virus–like particles combined with novel adjuvant systems enhance virus‐specific immune responses
Ming Qiao, Kazumoto Murata, Anthony R. Davis, Sook‐Hyang Jeong, T. Jake Liang – 30 December 2003 – We have previously described the generation of hepatitis C virus–like particles (HCV‐LPs) in insect cells and shown that immunization with HCV‐LPs elicited both humoral and cellular immune responses in mice. To further characterize the HCV‐LPs as a vaccine candidate, we evaluated the effects of adjuvant AS01B (monophosphoryl lipid A [MPL] and QS21), CpG 10105, and the combination of the 2 adjuvants on the immunogenicity of HCV‐LPs in AAD mice (transgenic for HLA‐A2.1).